Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.
Actively Recruiting
Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.
Actively Recruiting
This research aims to evaluate the effects of adding Vitamin D supplementation to standard immunochemotherapy in elderly patients diagnosed with Diffuse Large B-Cell Lymphoma or Follicular grade IIIb lymphoma. This open-label, randomized phase III trial compares two treatment approaches to understand whether Vitamin D affects outcomes in patients aged 65 and older undergoing immunochemotherapy. Participants are randomly assigned to one of two groups. Both groups receive a prephase of oral prednisone followed by six cycles of immunochemotherapy with R-CHOP or R-miniCHOP every 21 days. The experimental group also receives Vitamin D supplementation starting before treatment and continuing through immunochemotherapy according to a set schedule, including loading doses based on baseline Vitamin D levels and weekly maintenance. Patients may continue Vitamin D supplementation after treatment for up to two years. During the study, participants undergo baseline assessments and are monitored regularly through the treatment cycles. Researchers track progression-free survival over 54 months as the primary outcome, along with overall survival, response rates, Vitamin D levels, physical functioning, and fatigue. Safety and treatment adherence are also monitored, with follow-up visits extending up to several years to evaluate long-term outcomes.
Actively Recruiting
Researchers are creating a national registry in Italy for people with Noonan syndrome, a rare genetic condition that can affect growth, the heart, and other parts of the body. Because this condition is uncommon, doctors have limited information about its progression. This study aims to gather detailed data on signs, symptoms, gene changes, growth patterns, health problems, and the effects of growth hormone treatment over time. Doctors at participating centers will securely enter health information of individuals with genetically confirmed Noonan syndrome into an online platform. This includes personal details, medical history, genetic test results, treatments, and heart check results, with follow-up heart evaluations approximately every two years. The registry will include both existing patients and newly diagnosed individuals, with updates over time. Participants will be monitored through their ongoing medical care, with data collected on their health status and treatments. The study will last five years and aims to establish a comprehensive database to help guide long-term care recommendations and support future clinical trials. Participation is voluntary, and no new treatments are tested in this study.
Actively Recruiting
Researchers are studying how diets supplemented with polyunsaturated fatty acids PUFAs from animal or plant sources affect chronic inflammation linked to cardiovascular risk. The study focuses on people over 55 with moderate to high cardiovascular risk but without established cardiovascular disease. It aims to better understand how these dietary changes influence a lipid and inflammation-related risk score and improve overall cardiovascular prevention by addressing chronic inflammation. Participants are randomly assigned to one of three diets fish oil supplementation providing omega-3 fatty acids DHA and EPA, camelina oil supplementation rich in alpha-linolenic acid ALA plus vitamin E, or a regular non-enriched diet with vitamin E. The study product is taken daily for 12 weeks, with doses standardized to ensure comparable vitamin E intake. The supplementation is administered before meals, and all products are provided by the study team. During the study, participants undergo a baseline clinical visit with blood sampling, heart rate, blood pressure, and waist circumference measurements, and complete a dietary questionnaire. After 12 weeks, these assessments are repeated along with monitoring diet tolerance and any clinical events. Blood samples are stored and analyzed centrally to evaluate changes in lipid and inflammatory biomarkers. The study plans to enroll 324 participants, with outcomes measured primarily by changes in a lipidomicinflammation-based risk score over 12 weeks.